Meeting the Nasdaq minimum bid price requirement is a critical regulatory compliance achievement for Cyclacel Pharmaceuticals. It removes the immediate threat of delisting, which can be detrimental to stock liquidity and investor perception. This news is likely to be viewed positively by the market in the short term, potentially leading to an uptick in the stock price as it reassures investors of the company's continued presence on a major exchange.